NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Sees Unusually-High Trading Volume

Shares of NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) saw unusually-strong trading volume on Monday . Approximately 2,862,552 shares changed hands during mid-day trading, an increase of 151% from the previous session’s volume of 1,140,443 shares.The stock last traded at $0.62 and had previously closed at $0.59.

Several equities research analysts have recently commented on NBY shares. Zacks Investment Research upgraded shares of NovaBay Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Wednesday, November 20th. LADENBURG THALM/SH SH started coverage on shares of NovaBay Pharmaceuticals in a report on Wednesday, September 18th. They issued a “buy” rating and a $1.10 price target for the company.

The firm’s fifty day moving average price is $0.68 and its 200 day moving average price is $1.02.

A hedge fund recently bought a new stake in NovaBay Pharmaceuticals stock. Jane Street Group LLC acquired a new position in NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 37,287 shares of the biopharmaceutical company’s stock, valued at approximately $63,000. Jane Street Group LLC owned about 0.18% of NovaBay Pharmaceuticals as of its most recent SEC filing.

About NovaBay Pharmaceuticals (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

Further Reading: Hang Seng Index (HSI)

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.